p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
about
Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability.HNF-1β in ovarian carcinomas with serous and clear cell change.Genetics of endometrial cancersOvarian cancer: pathology, biology, and disease modelsPathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor developmentOvarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinomaSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesOvarian clear cell adenocarcinoma: a continuing enigmaMolecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis.Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesisPathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma.
P2860
Q27012348-1729AECE-D610-4536-99EC-B51891F0D0EDQ30437752-A4FFA5C9-765B-4A4D-B706-089EA5D28349Q31107824-04797279-201A-43C6-B085-8F039D7789F4Q33647555-940A88D4-1753-4510-A7CD-B4A91DFE0D9FQ33781274-FD422E3D-2EE5-499A-843F-88A389B22E34Q33807748-07B4B99C-BCA2-42BA-A57D-9AE883FE6AC7Q34771886-D42181FC-1582-4206-87C9-3D59D308DF3CQ35098091-3EE01DAE-7F58-470A-89CD-BC76FC2E16A1Q35843312-61321B12-F731-4286-AECB-C8653DE71E3FQ35892810-CC5EF363-FE1E-4BF7-9E90-EFBD85FCF51BQ36026090-028314AF-979A-4B96-BAED-3BA40F7A2A2DQ36261402-0411E888-C85C-4AE8-AA09-6270F09938E3Q36750166-EA58AE77-76FD-4A2F-AB62-B4B6DBE82042Q36826591-DA00D2B8-D1E1-4169-973B-9827532D0AE5Q36868408-757BF251-2882-4245-BCF4-3A4F065A2362Q37101060-F19E89AE-F5A9-487F-BD16-5E39856D99A4Q40765757-68F54A13-2587-4DDF-BF0E-B5C4616A6D61Q45201949-329CBB42-2C3C-4F1F-9257-67C4EFB2FCC6Q47248242-E0F00CE4-BBF3-448D-BEF1-AF3A69B7DE95Q53038737-F8788F31-B285-4D07-AC84-3BB2226BE8E3Q53325005-B55D343A-21D4-40D8-A2A8-2490F841A6EFQ54705314-9421B10A-48C6-41A9-84BF-B54ADAFE0F52
P2860
p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@en
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@nl
type
label
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@en
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@nl
prefLabel
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@en
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@nl
P2093
P1433
P1476
p53 mutations and overexpressi ...... cer but not clear cell cancer.
@en
P2093
Akihiko Sekizawa
Hiroshi Saito
Junko Otsuka
Miki Kushima
Reiko Makino
Takashi Okai
Tsuyoshi Okuda
Yuzuru Kuwano
P304
P356
10.1016/S0090-8258(02)00149-X
P407
P577
2003-03-01T00:00:00Z